InnovAge's Third Act: A Best-Ever Year, Instantly Repriced Against a Thinner Rate Tailwind

Adjusted EBITDA up 175% in fiscal 2026 — but guidance and a new '3.0' strategy pivot carry the story, not rates.

INNV · Earnings Call · 2026-09-08

The best year in InnovAge's public history — immediately reframed as a test

InnovAge, the largest for-profit operator of PACE (Program of All-Inclusive Care for the Elderly), just closed fiscal 2026 with adjusted EBITDA of $94.6M, up roughly 175% from $34.5M a year earlier, on revenue of $989.7M (+15.9%). Census grew 6.3% to about 8,230 participants across 20 centers, and center-level contribution margin expanded 500 basis points to 23.0%. CEO Patrick Blair did not undersell it: “Adjusted EBITDA increased approximately 175% compared with fiscal 2025, and we believe we are ahead of schedule to achieve our 10-plus percent long-term adjusted EBITDA margin target.” — Patrick Blair, CEO · 2026-09-08 Then he guided fiscal 2027 to $105–$115M EBITDA on $1.05–$1.085B of revenue — roughly 10.3% margins — against a Medicare rate increase of only 1.5%–2.0% and the continuing V28 risk-adjustment transition. CFO Ben Adams framed the year bluntly: “we expect fiscal 2027 to be a year focused on preserving and expanding upon the progress we've made while navigating a more challenging rate environment and making disciplined margin management a key priority.” — Benjamin Adams, CFO · 2026-09-08 The revenue tailwind that powered FY26 is thinning; execution is now the whole story. Tellingly, the rate environment keyword that topped the prior quarter's theme list has slid far down the current-quarter ranking, while interdisciplinary team and total cost of care have reclaimed the top two slots — a shift from "what will states pay us" back to "how do we run the model." Revenue has compounded every year of the turnaround, reaching $252M in the latest reported quarter (+15% yoy), and gross margin now sits at 24.2%, up 5.5 points year-over-year and 22 points over six years — the same process standardization the company is now trying to push further with data and AI.

From repair to scale: the 'InnovAge 3.0' pivot

The genuinely new material is strategic, not financial. Blair introduced a three-chapter framing — 1.0 building the platform, 2.0 strengthening it, 3.0 scaling it.

If 1.0 is about building the platform and 2.0 is about strengthening it, 3.0 is about scaling its capabilities and capitalizing on the opportunity in front of us.
Patrick Blair, CEO · 2026-09-08

Practically, that means a more explicit appetite for M&A and joint ventures, a high bar for de novos, and a fresh operating chief — Jen Browne, hired from Optum and Strive Health — to drive consistency across centers. This reverses a long-running theme: the de novo market concept, once the company's dominant strategic topic, has faded to a footnote, and de novo losses are guided at just $0.4–$0.8M for FY27 versus double-digit millions in prior years. On the May call Blair had already signaled the pivot: “M&A is clearly one of them. There are a lot of PACE programs across the country... we have the ability to bolt on and smaller PACE programs that were maybe struggling to grow.” — Patrick Blair, Chief Executive Officer · 2026-05-05 A prior-quarter quote also flags that the internal efficiency work is only half done — Blair said he'd put the clinical-value initiatives at “about 50% there” — Patrick Blair, Chief Executive Officer · 2025-11-04 — which is precisely why the FY27 margin defense leans so heavily on execution.

The two wild cards: federal policy and AI

The most company-unique theme on the call was Washington. Blair argued federal interest in PACE is as strong as it has been in years, split into two tracks: modernizing the existing program (easier enrollment, easier market entry) and exploring adjacent populations. The adjacency pitch centers on Medicare beneficiaries with functional impairment who "sit upstream of PACE." “It's really about making it easier to enroll in PACE, building awareness of PACE... as well as the ability to apply and expand into new territories.” — Patrick Blair, CEO · 2026-09-08 HHS Secretary Robert F. Kennedy Jr. recently toured a Colorado center, and Blair cited an ASPE study showing PACE participants had fewer hospitalizations and lower mortality than comparable Medicare Advantage members. None of it is in guidance — pure optionality. The second lever is AI, and here InnovAge is riding a wave visible across this earnings cycle (Asana's "AI Teammates," Braze's "advanced AI," Ambra's "AI agent"). InnovAge's version is deliberately unglamorous: two piloted clinical agents — a geriatric consultation agent and a medication-optimization agent — that surface clinical information inside physician workflows, plus scheduling and transportation analytics. Every use case is tested, measured, then scaled or shelved, with human judgment kept firmly with the provider.

What the tape is already saying

The market has voted on the turnaround: the stock is up roughly 33% over the last 90 days (and within ~9% of its July high), even though it remains down more than 50% from its 2021 IPO levels on a market cap near $1.0B. The balance sheet supports the pivot — effective net cash has roughly doubled year-over-year to about $80M, while leverage has stayed modest. The one blemish is accounting, not operations: a GAAP operating margin of negative 11.5% reflects one-time litigation accruals, not the run-rate, as the company itself noted when it said it "would have generated strong net income for the year" but for those charges. So the setup is clean and a little uncomfortable: InnovAge has spent four years proving it can fix a broken platform, and now it is asking investors to believe it can grow one — with rates no longer doing the heavy lifting. The next two quarters of census cadence and center-level margin will tell whether 3.0 is a real inflection or a well-dressed version of the same story.